文献速递妇科

妇科癌症患者益生菌与益生元使用评估:一项系统综述

Assessment of probiotic and prebiotic use in gynecologic cancer patients: a systematic review.
PubMed 文献 · Am J Obstet Gynecol · 2025-10-08

本系统综述检索PubMed、Embase和Scopus(2023年3月检索,更新至2025年9月),纳入9项随机对照试验共663例妇科癌症患者,评估益生菌/益生元对临床结局、治疗疗效、生活质量、安全性和转化终点的影响。益生菌可显著降低放疗所致腹泻的发生率和严重程度、改善粪便性状并减少止泻药使用(P<.05),单用益生元获益有限。

要点

  • 益生菌显著降低妇科癌症患者放疗所致腹泻的发生率和严重程度(P<.05)。
  • 单用益生元/膳食纤维对放疗所致毒性获益有限。
  • 尚无试验评估化疗、免疫治疗结局或生存终点。

核心结论

  • 益生菌补充在降低妇科癌症患者放疗所致胃肠道毒性方面显示出一致获益,而单用益生元疗效有限。
  • 证据缺口包括对化疗、免疫治疗、肿瘤学结局和生存的影响。
  • 制剂异质性限制临床适用性,需要标准化的菌株特异性试验。
  • 未来研究应评估长期肿瘤学结局、优化微生物组导向干预,并在免疫抑制人群中确立安全性。

研究设计与样本

  • 系统综述,检索PubMed、Embase和Scopus,于2023年3月进行检索并更新至2025年9月,同时检索ClinicalTrials.gov和参考文献列表等灰色文献。
  • 纳入标准为随机对照试验和前瞻性干预研究,对象为接受治疗的妇科癌症(宫颈、子宫内膜、卵巢、子宫和外阴)女性,干预为益生菌、益生元或膳食纤维补充。
  • 排除回顾性研究、病例报告、综述、会议摘要及无癌症相关结局的研究。
  • 由三名独立评审员使用Covidence筛选研究,分歧通过共识或裁决解决;采用Cochrane Risk of Bias 2.0工具评估偏倚风险。
  • 因菌株、剂量和结局存在异质性,采用结构化叙述性综合而非Meta分析。

主要发现

  • 从2308条筛选记录中纳入9项随机对照试验,共663例患者。
  • 7项研究评估益生菌,2项评估益生元/纤维;多数聚焦宫颈癌(n=415)和子宫内膜癌(n=170)患者的放疗所致毒性。
  • 益生菌显著降低放疗所致腹泻的发生率和严重程度、改善粪便性状并减少止泻药使用(P<.05)。
  • 单用益生元显示出极小获益。
  • 一项围手术期研究发现益生菌加速肠道恢复并减少术后并发症。

关键数值与推荐

  • 益生菌显著降低放疗所致腹泻的发生率和严重程度、改善粪便性状并减少止泻药使用(P<.05)。
  • 单用益生元显示出极小获益。
  • 一项围手术期研究发现益生菌加速肠道恢复并减少术后并发症。
  • 三项转化研究显示益生菌降低肠道通透性但未改变微生物组成。
  • 不良事件不常见,未发现重大安全性问题。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 因菌株、剂量和结局存在异质性,采用结构化叙述性综合而非Meta分析。
  • 制剂异质性限制临床适用性。
  • 证据缺口包括对化疗、免疫治疗、肿瘤学结局和生存的影响。
  • 需要标准化的菌株特异性试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate evidence on the impact of probiotics and prebiotics on clinical outcomes, treatment efficacy, quality of life, safety, and translational endpoints in patients with gynecologic cancers. DATA SOURCES: A systematic search of PubMed, Embase, and Scopus was conducted in March 2023 and updated through September 2025. Gray literature sources (ClinicalTrials.gov, reference lists) were also reviewed. STUDY ELIGIBILITY CRITERIA: Eligible studies included randomized controlled trials and prospective interventional studies in women with gynecologic cancers (cervical, endometrial, ovarian, uterine, and vulvar) undergoing treatment. Interventions were probiotic, prebiotic, or dietary fiber supplementation. Eligible outcomes included treatment toxicity, stool consistency, quality of life, postoperative outcomes, oncologic outcomes, safety, and microbiome endpoints. Exclusions were retrospective studies, case reports, reviews, conference abstracts, and studies without cancer-related outcomes. STUDY APPRAISAL AND SYNTHESIS METHODS: Three independent reviewers screened studies using Covidence, with disagreements resolved by consensus or adjudication. Risk of bias was assessed with the Cochrane Risk of Bias 2.0 tool. Due to heterogeneity in strains, dosing, and outcomes, structured narrative synthesis was conducted rather than meta-analysis. RESULTS: From 2308 screened records, 9 randomized controlled trials involving 663 patients were included. Seven studies evaluated probiotics and 2 assessed prebiotics/fiber. Most focused on radiation-induced toxicity in cervical (n=415) and endometrial cancer (n=170) patients. Probiotics significantly reduced incidence and severity of radiation-induced diarrhea, improved stool consistency, and decreased antidiarrheal use (P<.05). Prebiotics alone showed minimal benefit. One perioperative study found probiotics accelerated bowel recovery and reduced postoperative complications. Three translational studies showed probiotics reduced gut permeability but did not alter microbial composition. No trials examined chemotherapy or immunotherapy outcomes, progression-free survival, or overall survival. Adverse events were infrequent and no major safety concerns were identified. CONCLUSION: Probiotic supplementation demonstrates consistent benefit in reducing radiation-induced gastrointestinal toxicity in gynecologic cancer patients, while prebiotics alone show limited efficacy. Evidence gaps include effects on chemotherapy, immunotherapy, oncologic outcomes, and survival. Heterogeneity in formulations limits clinical applicability, and standardized strain-specific trials are needed. Future research should evaluate long-term oncologic outcomes, optimize microbiome-directed interventions, and establish safety in immunocompromised populations.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Chalif J, Morton M, Haight P, et al. Assessment of probiotic and prebiotic use in gynecologic cancer patients: a systematic review. Am J Obstet Gynecol. 2025. PMID: 41072704. doi:10.1016/j.ajog.2025.09.042

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。